Related Experiment Video
Updated: Jun 15, 2025

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology
Published on: March 21, 2018
Chromothripsis-Mediated Small Cell Lung Carcinoma
Natasha Rekhtman1, Sam E Tischfield2, Christopher A Febres-Aldana1,3
1Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract:
Small cell lung carcinoma (SCLC) is a highly aggressive malignancy that is typically associated with tobacco exposure and inactivation of RB1 and TP53 genes. Here, we performed detailed clinicopathologic, genomic, and transcriptomic profiling of an atypical subset of SCLC that lacked RB1 and TP53 co-inactivation and arose in never/light smokers. We found that most cases were associated with chromothripsis-massive, localized chromosome shattering-recurrently involving chromosome 11 or 12 and resulting in extrachromosomal amplification of CCND1 or co-amplification of CCND2/CDK4/MDM2, respectively. Uniquely, these clinically aggressive tumors exhibited genomic and pathologic links to pulmonary carcinoids, suggesting a previously uncharacterized mode of SCLC pathogenesis via transformation from lower-grade neuroendocrine tumors or their progenitors. Conversely, SCLC in never-smokers harboring inactivated RB1 and TP53 exhibited hallmarks of adenocarcinoma-to-SCLC derivation, supporting two distinct pathways of plasticity-mediated pathogenesis of SCLC in never-smokers. Significance: Here, we provide the first detailed description of a unique SCLC subset lacking RB1/TP53 alterations and identify extensive chromothripsis and pathogenetic links to pulmonary carcinoids as its hallmark features. This work defines atypical SCLC as a novel entity among lung cancers, highlighting its exceptional histogenesis, clinicopathologic characteristics, and therapeutic vulnerabilities. See related commentary by Nadeem and Drapkin, p. 8.
Insights
Atypical small cell lung carcinoma (SCLC) lacking RB1/TP53 alterations shows distinct genomic features, including chromothripsis, and links to pulmonary carcinoids. This identifies a novel SCLC entity with unique origins and therapeutic vulnerabilities.
Area of Science:
- Oncology
- Genomics
- Pathology
Background:
- Small cell lung carcinoma (SCLC) is an aggressive cancer typically linked to smoking and RB1/TP53 gene inactivation.
- Understanding SCLC heterogeneity is crucial for developing targeted therapies.
Purpose of the Study:
- To characterize an atypical SCLC subset lacking RB1 and TP53 co-inactivation in never/light smokers.
- To elucidate the distinct pathogenetic mechanisms and genomic alterations in this SCLC subtype.
Main Methods:
- Detailed clinicopathologic, genomic, and transcriptomic profiling.
- Analysis of chromosomal alterations, including chromothripsis.
- Comparative analysis with pulmonary carcinoids and adenocarcinoma-derived SCLC.
Main Results:
- Atypical SCLC cases showed recurrent chromothripsis involving chromosomes 11 or 12, leading to CCND1 or CCND2/CDK4/MDM2 amplification.
- These tumors displayed genomic and pathologic links to pulmonary carcinoids, suggesting a novel SCLC origin.
- SCLC in never-smokers with RB1/TP53 inactivation showed links to adenocarcinoma, indicating distinct SCLC pathogenesis pathways.
Conclusions:
- Atypical SCLC lacking RB1/TP53 alterations represents a novel entity with unique histogenesis and genomic features.
- Chromothripsis and links to pulmonary carcinoids are hallmarks of this SCLC subset.
- Identifying distinct SCLC subtypes is essential for understanding therapeutic vulnerabilities and improving patient outcomes.
More Related Videos
Related Concept Videos
Cancers Originate from Somatic Mutations in a Single Cell
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Non-LTR Retrotransposons
Abnormal Proliferation
Replicative Cell Senescence
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

